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Gallstone disease and its comorbidities continue to rep-
resent a healthcare and economic challenge in the devel-
oped world (1). Our understanding of the pathogenesis of 
cholesterol gallstone disease includes both genetic and en-
vironmental risk factors, events that converge on pathways 
that regulate hepatic cholesterol metabolism and canalicu-
lar lipid secretion (2, 3). Genome-wide association studies 
implicate susceptibility loci with functions in cholesterol 
metabolism and transport, in particular the canalicular 
cholesterol transporter ABCG5/G8 (4, 5). Other studies, 
using inbred mouse strains, have led to the identification 
of quantitative trait loci and corresponding positional 
candidate genes that predispose to lithogenic diet (LD)-
induced gallstones (6, 7).
Studies examining environmental and genetic risk fac-
tors suggest that several distinct metabolic pathways mod-
ify gallstone susceptibility. These pathways include those 
regulated by nuclear hormone receptors involved in sterol 
and bile acid sensing (8, 9), as well as pathways more 
broadly involved in hepatic lipid utilization and metabolic 
channeling. For example, mice with germline deletion of 
L-Fabp, while protected against diet-induced hepatic steatosis 
(10, 11) demonstrated increased LD-induced gallstone for-
mation, at least in part through augmented canalicular cho-
lesterol secretion (12). Similarly, germline deletion of Elovl6 
attenuated hepatic steatosis in Ldlr KO mice, yet enhanced 
gallstone susceptibility (13). Here, we asked whether the 
multiligand class B scavenger receptor CD36 might play a 
role in modifying hepatic cholesterol utilization and ex-
port. This possibility was in part predicated on findings that 
mouse hepatic CD36 expression is increased in response to 
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high-fat diet-induced obesity and other findings that ade-
noviral-mediated hepatic CD36 overexpression increased 
hepatic FFA uptake and steatosis (14). In addition, CD36 
has been shown to regulate cholesterol uptake, utilization, 
and secretion from both the small intestine (15, 16) and 
mouse peritoneal macrophages (17).
Beyond the metabolic alterations alluded to above, there 
is a role for altered gallbladder motility in promoting gall-
stone susceptibility, evidenced by findings in both Cck KO 
mice and in Cckr1 KO mice (18, 19). These findings, cou-
pled with findings that CD36-dependent signaling pro-
motes secretin and cholecystokinin (CCK) release from 
enteroendocrine cells (20), raised the question of whether 
CD36 might function more broadly in modifying gallstone 
susceptibility, specifically via alterations in gallbladder con-
tractility. Here, we show that germline Cd36 KO mice are 
protected against LD-induced gallstones via mechanisms 
including alterations in biliary cholesterol secretion, bile 
acid composition, and enhanced gallbladder contractility.
MATERIALS AND METHODS
Animals and diets
All animals were maintained in a C57BL6/J background and 
housed on a 12 h light-dark cycle, in a full-barrier facility. Ten- to 
12-week-old male mice were fed either standard rodent chow 
(PicoLab Rodent Diet 20, fat 4.5%, cholesterol 0.015%) or an LD 
(Research Diet no. 960393, fat 18.8%, cholesterol 1.2%, and cholic 
acid 0.5%) for 2–4 weeks, as indicated. L-Fabp/ mice (12) and 
Cd36/ mice (21) were used in crosses to generate a line of com-
pound Cd36, L-Fabp double KO mice (hereafter referred to as 
DKO). Cd36 conditional KO mice were generated from Cd36flox/flox 
mice (22) crossed into either Albumin-Cre or Villin-Cre lines (Jax) 
to generate the compound line of tissue-specific KO (either liver- 
or intestine-specific) mice. Age-matched and cohoused littermates 
were used as controls. All animal protocols were approved by the 
Washington University Animal Studies Committee and followed 
guidelines outlined by the National Institutes of Health.
Tissue and serum lipid determinations
Animals were euthanized after a 4 h fast. Liver and serum were 
collected and frozen at 80°C until analyzed. Serum triglyceride 
and cholesterol were measured by using reagents from Wako 
(Neuss, Germany), an L-Type Triglyceride M Kit (catalog nos. 
465-09791 and 461-09891), and the cholesterol E kit (catalog no. 
439-17501). Hepatic or, where indicated, gallbladder lipids were 
extracted by using chloroform: methanol (2:1) and triglyceride, 
cholesterol, free cholesterol, free fatty acids, and phospholipids 
enzymatically with the indicated Wako reagent kits: the L-Type 
Triglyceride M Kit, the cholesterol E kit, the free cholesterol E kit 
(catalog no. 435-35801), the HR series NRFA-HR2 kit (catalog nos. 
991-34891 and 995-34791), and the phospholipid C kit (catalog no. 
433-36201).
Gallstone analysis and gallbladder bile cholesterol 
saturation index
Animals were fed a LD for 4 weeks as indicated in the relevant 
figure legends and euthanized after a 4 h fast. Fresh gallbladder 
bile was immediately analyzed by polarizing microscopy using a 
visual scale with the following criteria: 0, absence of cholesterol 
monohydrate crystals (ChMCs), 1, small number of ChMCs (<3 per 
high power field); 2, many ChMCs (3 per high power field); 
3 = aggregated ChMCs; and 4 = presence of “sandy” light-translucent 
stones or “solid” light-opaque stones (7). Gallbladder bile choles-
terol content was measured enzymatically after chloroform: 
methanol (2:1) extraction. Gallbladder bile phospholipids and 
bile acid content were analyzed enzymatically by using the total 
bile acids assay kit (BQ 092A-EALD, BQ Kits, San Diego, CA). 
Cholesterol saturation indices in gallbladder bile were calculated 
by using published parameters (23).
Biliary lipid secretion and bile acid pool size
Mice were fed a LD for 2 weeks and anesthetized after a 4 h fast. 
An external bile fistula was established surgically, and bile samples 
collected during the first 15 min were discarded. Bile samples were 
collected for another 60 min and used for biliary lipid secretion 
analysis. Hepatic bile volume was determined gravimetrically assum-
ing a density of 1 g·ml1. Biliary phospholipids, cholesterol, and to-
tal bile acid content were determined enzymatically. Biliary lipid 
secretion values are presented as nmol/min/kg body weight (bw). 
Individual bile acid species were determined by using HPLC as pre-
viously described (12) and with commercially obtained standards. 
The hydrophobicity index was calculated by using published param-
eters (24). Bile acid pool size and fecal bile acids excretion were de-
termined in groups of mice fed a LD for 2 weeks. For bile acid pool 
size, the liver, gallbladder, and intestine were homogenized to-
gether, and bile acid content was measured as previously detailed 
(12). For fecal bile acid excretion, feces from individual animals 
were collected for up to 72 h. Feces were homogenized, and bile 
acid content was determined enzymatically.
Gene expression analysis
Hepatic total RNA or proximal intestinal RNA was extracted 
and cDNA was prepared by using an ABI high-capacity cDNA re-
verse transcription kit with 1 µg of total RNA. Real-time quantita-
tive PCR used cDNAs from four to six animals per group and was 
performed in triplicate on an ABI Prism7000 sequence detection 
system using SYBR Green PCR Master Mix (Applied Biosystems) 
and primer pairs (provided on request) designed by Primer Ex-
press software (Applied Biosystems). Relative mRNA abundance is 
expressed as fold change to WT control after normalization to own 
GAPDH. To detect hepatic CD36 and L-Fabp protein, 50 mg of 
liver was homogenized in 0.5 ml of buffer containing 25 mM 
HEPES, 150 mM NaCL, 0.5 mM EDTA, 0.1% SDS, 1% Triton, and 
protease inhibitors, by using the Bullet BlenderR system (Next Ad-
vance) with 1 mm zirconium oxide beads. Aliquots of 50 µg of 
protein were separated by 4–20% SDS-PAGE gel. Samples of termi-
nal ileum protein were used to prepare total and membrane ex-
tracts as described (12, 25) by using the Bullet BlenderR system 
with 1 mm steel beads. In brief, approximately 50–100 mg of full-
thickness ileum was homogenized in 0.8 ml of lysis buffer (250 mM 
sucrose and 10 mM Triethanolamine-HCL, pH 7.6) containing 
protease inhibitors (Complete protease inhibitor mixture, Roche 
Diagnostics). The crude preparation was centrifuged at 2,500 g for 
10 min, and the supernatant was recentrifuged at 30,000 g for 
60 min at 4°C by using a Beckman MLA-130 rotor. The resulting 
membrane pellet was resuspended in solubilization buffer [15% 
SDS, 8 M Urea, 10% (w/v) sucrose, 62.5 mM Tris-HCL, and 5 mM 
dithiothreitol, pH 6.8]. Membrane proteins (50 µg) were sepa-
rated on 10% SDS-PAGE gel, transferred to Immobilon®-P mem-
branes (Millipore, Billerica, MA), and immunoblotted with 1:2,000 
goat anti-mouse CD36 (16), 1:2,000 rabbit anti-mouse L-Fabp 
(26), 1:300 rabbit anti-mouse Fgf15, and 1:1,000 monoclonal rab-
bit anti-mouse Asbt antibody (generous gifts from Dr. Paul A Daw-
son), and quantitated by Kodak Image software.
Gallbladder contractility studies. Gallbladders were taken 
from age- and sex-matched (male) chow-fed WT and Cd36/ 
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mice. Both surfaces of the excised gallbladder were gently cut and 
washed with PBS and attached to a force transducer (Radnoti 
8-chamber tissue-organ bath system) exactly as described (27). 
Gallbladders were immersed in warmed, oxygenated buffer for 
30 min before the addition of the indicated concentrations of 
methacholine and KCl. Resting tension of 0.5 g was applied after 
each treatment as previously described (28).
Statistical analysis
Statistical significance was determined with one-way ANOVA 
for multiple group comparisons and t-testing as a post hoc test 
for comparing different pairs using GraphPad Prism 7 software 
(GraphPad, San Diego, CA). Data are expressed as the mean ± SE 
unless otherwise noted.
RESULTS
Cd36 deletion protects against LD-induced gallstones and 
attenuates gallstone susceptibility in L-Fabp KO mice
Our first objective was to ascertain a role for CD36 in LD-
induced gallstone susceptibility. Mice of the indicated geno-
type (Fig. 1A) were studied after consuming a LD for 4 
weeks, with the data showing that Cd36/ mice (Fig. 1A) 
exhibited a striking reduction in gallstone incidence with 
correspondingly reduced gallstone score and reduced cho-
lesterol saturation index (Fig. 1B). Furthermore, when 
crossed into germline L-Fabp/ mice, both Cd36/and 
the compound DKO mice (Fig. 1A, B) were protected, as 
evidenced by the visually clear appearance of the gallblad-
der, decreased cholesterol saturation index, and reduced 
gallbladder volume (Fig. 1B). We observed increased abun-
dance of L-Fabp protein in livers from LD-fed Cd36 KO 
mice compared with WT controls (Fig. 1A), an observation 
whose underlying mechanisms remain to be elucidated. 
However, these findings point to a role of CD36 as a modi-
fier of murine gallstone susceptibility in mice either WT or 
null for the L-Fabp allele.
Gallstone protection in Cd36/ mice is associated with 
alterations in biliary lipid secretion
Hepatic lipid content across the genotypes in LD-fed 
mice indicated no major differences in total or free choles-
terol content, but revealed increased bile acid content in 
both Cd36/ and DKO mice (Table 1). We next examined 
the concentration and relative distribution of the most 
abundant individual bile acid species from newly secreted 
bile samples in each genotype. These data revealed in-
creased biliary concentration of taurobetamuricholic acid 
in LD-fed Cd36/ mice (Fig. 2A) with a shift in relative Fig. 1. Cd36/ mice are protected against gallstones, and Cd36 
deletion confers protection in L-Fabp/ mice (DKO mice) after 4 
weeks of LD feeding. A: Hepatic CD36 and L-Fabp protein expres-
sion were determined by Western blotting of total liver extracts. 
CD36 protein was not detected in either Cd36/ mice or DKO 
liver, and L-Fabp protein was likewise not detected in either 
L-Fabp/ or DKO liver as predicted. B: Representative gross ap-
pearances of gallbladder after 4 weeks of LD feeding. Gallbladders 
from WT and L-Fabp/ mice appear opaque with visible solid 
stones, whereas gallbladders from Cd36/ mice and DKO are 
transparent without visible stones. Gallstone incidence (C) and gall-
stone score (D) were significantly reduced in both Cd36/ mice 
and in DKO mice. E: Gallbladder volume was determined gravi-
metrically (Materials and Methods). F: Cholesterol saturation index 
(CSI) of gallbladder bile was calculated as described in Materials 
and Methods. Cd36/ and DKO mice demonstrate a similar de-
crease in CSI compared with WT and L-Fabp/ mice, n = 6–12 
mice per group. The data associated with different superscript 
letters are significantly different (P < 0.05). The data reflect the 
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taurobetamuricholic acid distribution favoring enrich-
ment in both Cd36/ and DKO mice (Fig. 2B). The net 
impact of these relatively subtle, albeit significant, differ-
ences in bile acid species includes a significant decrease in 
hydrophobicity index (24) in both Cd36/ and DKO mice 
(Fig. 2C). Daily fecal bile acid excretion (Fig. 2D) and total 
bile acid pool sizes (Fig. 2E) were comparable across the 
genotypes, suggesting that there were no major shifts in en-
terohepatic cycling.
We further examined biliary lipid secretion rates in the 
various genotypes, using a shorter (2 week) LD feeding in-
terval. This interval was selected to circumvent the inevita-
ble bile duct obstruction that accompanied the extensive 
gallstone formation in both WT and L-Fabp/ mice noted 
above. Those findings revealed increased biliary choles-
terol secretion in L-Fabp/ mice compared with both WT 
and Cd36/ mice (Table 2). There was a trend to de-
creased biliary cholesterol secretion in Cd36/ mice (175 
nmol/min/kg bw) compared with WT controls (210 nmol/
min/kg bw) and in DKO mice (222 nmol/min/kg bw) com-
pared with L-Fabp/ mice (298 nmol/min/kg bw), with-
out changes in bile flow rate by genotype (Table 2). Taken 
together, these findings suggest that altered biliary bile 
acid composition and attenuated cholesterol secretion in 
LD-fed Cd36/ mice may in combination contribute to the 
protection observed against gallstone formation.
Gallstone protection in Cd36/ mice is associated with 
alterations in genes regulating hepatic and intestinal 
cholesterol and bile acid metabolism
We next sought to understand the mechanisms underly-
ing the alterations in biliary lipid secretion noted above by 
profiling the expression of several mRNAs involved in he-
patic cholesterol and bile acid homeostasis. We observed 
decreased expression of hepatic Cyp7a1 in L-Fabp/ mice 
as previously demonstrated (12) and also in both geno-
types of Cd36/ mice, which was accompanied by in-
creased Cyp8b1 expression in LD-fed Cd36/ and DKO 
mice (Fig. 3A). The increased expression of hepatic Cyp8b1 
mRNA in Cd36/ and DKO mice was not accompanied by 
increased biliary taurocholate concentration, as might be 
predicted (29, 30), but it bears emphasis that those bile 
acid distribution data (Fig. 2A and above) reflect mice fed 
supplemental cholic acid as part of the LD regimen. We 
also observed decreased expression of HMGR mRNA in 
Cd36/ and DKO mice, findings suggesting that de novo 
hepatic cholesterol production may be decreased, a pos-
sibility consistent with the decreased secretion of biliary 
cholesterol noted above, as well as earlier findings suggest-
ing decreased de novo lipogenesis in Cd36/ mice (31).
We next turned to an examination of a panel of intesti-
nal genes involved in cholesterol and bile acid metabo-
lism, in part guided by previous findings of regionally 
specific adaptive alterations in their expression in germ-
line Cd36/ mice (16). Our findings revealed decreased 
expression of NPC1L1 mRNA and protein in both Cd36/ 
and DKO mice (Fig. 3B, C) and increased expression of 
SRB1 in proximal intestinal samples (Fig. 3B, C) along 
with decreased mRNA abundance of ABCG5/G8 in germ-
line Cd36/ mice (Fig. 3B). These findings point to the 
possibility of altered intestinal cholesterol uptake and ab-
sorption in LD-fed Cd36/ and DKO mice, consistent with 
prior findings showing decreased cholesterol absorption 
in chow-fed Cd36/ mice (15, 16). We observed increased 
ileal expression of FGF15 expression in L-Fabp/ mice, but 
no change in ASBT expression in any genotype. Taken to-
gether, these findings suggest a range of adaptive changes 
in enterohepatic cholesterol and bile acid metabolism in 
LD-fed mice of the respective genotypes, raising the possi-
bility that either intestinal- or hepatic-specific Cd36 deletion 
might reveal a dominant pathway that confers protection 
against gallstones.
Neither intestine- nor liver-specific Cd36 deletion protects 
against LD-induced gallstone formation
We first examined intestine-specific Cd36 KO mice 
(Cd36-IKO), which were generated as previously docu-
mented (22) and fed a LD for 4 weeks. We found that both 
flox/flox (i.e., CD36 WT) controls and Cd36-IKO mice 
demonstrated gallstones, with no differences noted in any 
of the physical parameters of score or gallbladder volume 
(Fig. 4A–D). In addition, there were no differences by gen-
otype in hepatic lipid or bile acid content (Fig. 4E).
Using a similar approach, we generated liver-specific Cd36 
KO mice (Cd36-LKO) using Albumin-Cre mice (Jax). We 
documented liver-specific recombination at the Cd36 locus 
(Fig. 5A) and knockdown of hepatocyte CD36 (Fig. 5B), 
demonstrating that this strategy induced a decrease in 
CD36 expression in hepatocytes at baseline in chow-fed 
mice. Unexpectedly, we observed that total hepatic CD36 
abundance appeared slightly increased in LD-fed Cd36-
LKO compared with WT controls (Fig. 5C), suggesting that 
hepatocyte CD36 is likely only a minor component of over-
all hepatic CD36 expression. Both WT and Cd36 LKO mice 
demonstrated gallstones with no difference by genotype in 
TABLE 1. Hepatic lipid content in LD-fed mice of the indicated genotype
Genotype TC FC CE PL FFA BA
WT (6) 159.8 ± 22.9 27.5 ± 1.3 132.3 ± 22.9 85.6 ± 2.4 86.6 ± 5.6a 21.8 ± 9.1a
Cd36/ (6) 159.8 ± 10.4 31.0 ± 4.8 128.8 ± 10.9 92.5 ± 5.0 85.0 ± 4.9a 27.1 ± 15.1a
L-Fabp/ (5) 147.5 ± 11.6 24.0 ± 3.7 123.6 ± 12.3 95.8 ± 4.6 80.7 ± 9.1a 19.6 ± 4.1a
DKO (6) 159.4 ± 24.9 32.4 ± 1.9 127.0 ± 26.7 93.9 ± 2.7 132.9 ± 10.9b 33.2 ± 11.2a
Mice from four experimental groups (n per group) were fed a LD for 4 weeks. Hepatic lipids were extracted and 
analyzed (Materials and Methods). Hepatic lipid content is expressed as mean ± SE (µg/mg protein), except FFA 
(nmol/mg protein). The difference between values associated with different superscript letters for the parameters 
indicated in each vertical column is statistically significant (P < 0.05). BA, bile acid; CE, cholesteryl ester; FC, free 
cholesterol; FFA, free fatty acid; PL, phospholipid; TC, total cholesterol.
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any of the physical parameters of score or gallbladder vol-
ume and no differences by genotype in hepatic lipid or bile 
acid content (Fig. 5D–H). These findings, coupled with the 
data alluded to above, suggest that neither intestine-specific 
nor hepatocyte-specific Cd36 deletion alone can replicate 
the protection against LD-induced gallstones observed in 
germline Cd36/ mice.
Increased gallbladder contractility and reduced lipid 
accumulation in Cd36/ mice
We observed over the course of these studies that the gall-
bladders of Cd36/ mice appeared smaller and more con-
tracted than their WT controls (Fig. 6A). This observation 
prompted us to examine in more detail a possible role for 
CD36 in gallbladder function. We confirmed that CD36 
expression was undetectable in gallbladder mRNA from 
Cd36/ mice (Fig. 6B) and that gallbladder CD36 mRNA 
abundance was indistinguishable between WT (C57BL6/J), 
Cd36 flox controls, Cd36-IKO, and Cd36-LKO mice, sug-
gesting that neither intestine-specific (i.e., villin) nor liver-
specific (i.e., albumin) Cre drivers are active in gallbladder 
mucosa (Fig. 6C). Because prior work has shown a domi-
nant role for gallbladder hypomotility in increased gall-
stone susceptibility (19, 32), either via decreased CCK 
production or decreased CCK receptor expression (18), we 
examined gallbladder contractility using in vitro prepara-
tions of gallbladders from WT and Cd36/ mice (Materials 
and Methods). We observed that gallbladder contractility 
was increased in response to increasing doses of KCl 
and methacholine in Cd36/ mice (Fig. 6D, E) and that 
both the maximum force of contraction and the rate of 
smooth muscle contraction were increased in Cd36/ mice 
(Fig. 6F). These findings provide direct functional support 
for the suggestion that increased gallbladder contractility in 
Cd36/ and DKO mice might contribute to the protection 
observed against gallstone formation. We also examined 
parameters of inflammation in the gallbladders of LD-fed 
mice because prior work has suggested altered inflamma-
some induction in response to cholesterol-modulated path-
ways in atherosclerosis (33). These findings demonstrated 
an inconsistent adaptive pattern of mRNAs encoding proin-
flammatory and antiinflammatory mediators (Fig. 6G), with 
decreased expression of TNFa, but increased expression of 
TLR2, TLR4, IL1b, IL18, and Nlrp3 in Cd36/ mice. Histo-
logic examination of gallbladders from LD-fed WT and 
Cd36/ mice (Fig. 6H) revealed mucosal hypertrophy and 
increased submucosal thickening only in WT mice, with no 
obvious inflammatory changes evident in gallbladders from 
Cd36/ mice. Finally, we asked whether the changes ob-
served above in gallbladder function were associated with 
alterations in lipid accumulation. These findings revealed a 
trend to reduced accumulation of all lipid classes analyzed, 
with reduced free cholesterol reaching statistical signifi-
cance (Fig. 6I). Taken together, the findings indicate that a 
range of adaptive changes in gallbladder mucosal function 
and lipid accumulation likely contribute to the protection 
against gallstone formation.
DISCUSSION
The central findings of these studies are that Cd36/ 
mice are protected against LD-induced gallstones, through 
Fig. 2. Bile acid species, hydrophobicity, fecal bile acid excretion, 
and pool size in LD-fed mice. A, B: Biliary bile was collected from 
mice fed a LD for 2 weeks, and bile acid species were determined 
by HPLC as described in Materials and Methods. A: Biliary bile 
acid concentrations revealed an increase in taurocholate (TC) 
in L-Fabp/ mice with a decrease in taurochenodeoxycholate 
(TCDC) and taurodeoxycholate (TDC) concentration in Cd36/ 
and DKO mice compared with WT mice. B: Bile acid species distri-
bution was altered in Cd36/ and DKO mice, with increased abun-
dance of relatively hydrophilic bile acids tauro--muricholate 
(TMC), tauroursodeoxycholate (TUDC), and glycohyodeoxycho-
late (GHDC) (DKO), and decreased abundance of hydrophobic 
bile acids glycocholate (GC), TCDC, and glycochenodeoxycholate 
(GCDC). C: Hydrophobicity index (HI) of biliary bile from repre-
sentative animals of the four genotypes was calculated by using pub-
lished algorithms (Materials and Methods), revealing a significant 
reduction in Cd36/ and DKO mice compared with either WT or 
L-Fabp/ mice. D: Fecal bile acid excretion (mol per 100 g of bw 
per day) was comparable across the four genotypes. Mice were indi-
vidually housed, and feces were collected for up to 72 h. Fecal bile 
acids were extracted and quantitated enzymatically. E: Bile acid pool 
size (mol per 100 g of bw) was comparable in four genotypes. 
Liver, gallbladder, and the entire small and large intestine were 
pooled and subjected to ethanolic bile acid extraction. Total bile 
acid mass was measured enzymatically. The data are the mean ± SE 
(n = 4–8 per group). *Statistically significant differences (P < 0.05).
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adaptive mechanisms that include alterations in biliary 
cholesterol secretion and bile acid composition, as well as 
increased gallbladder contractility. In addition, Cd36/ 
mice crossed into L-Fabp/ mice were also protected, re-
versing the gallstone susceptibility phenotype previously 
observed in L-Fabp/ mice (12). However, and despite 
evidence demonstrating adaptive alterations in choles-
terol and bile acid metabolic pathways in both the intes-
tine and liver of germline Cd36/ mice, we found that 
neither intestine-specific nor liver-specific Cd36 deletion 
alone was capable of replicating the protection pheno-
type. Several aspects of these conclusions merit additional 
consideration.
Our initial hypothesis that Cd36/ mice might be pro-
tected against LD-induced gallstones was based on findings 
that these mice exhibit decreased intestinal cholesterol 
absorption and trafficking (15, 16). We reasoned that 
decreased cholesterol absorption in Cd36/ mice might 
prevent gallstone formation in a manner analogous to 
ezetimibe treatment (34, 35). However, it seemed equally 
plausible that Cd36/ mice might actually exhibit in-
creased susceptibility to LD-induced gallstone formation, 
based on other work showing that genetic strategies that 
mitigate high-fat diet-induced hepatic steatosis in mice 
(such as deletion of Elovl6 or of L-Fabp) demonstrated ac-
celerated gallstone formation (12, 13). The current find-
ings point to a gallstone-protection phenotype in LD-fed 
Cd36/ mice with changes in both intestinal and hepatic 
pathways contributing to complementary adaptations in 
cholesterol and bile acid metabolism, but with no domi-
nant protective mechanism.
Having demonstrated that germline Cd36/ mice were 
protected against LD-induced gallstone formation, we 
were initially surprised that intestine-specific Cd36 dele-
tion failed to replicate a protection phenotype. As noted 
above, this hypothesis was predicated in part on prior 
findings that intestinal cholesterol absorption is decreased 
in Cd36/ mice (15, 16). However, we recalled that the 
alterations observed in intestinal cholesterol uptake 
and processing in chow-fed Cd36/ mice are regionally 
specific (proximal greater than distal), and it remains 
to be determined whether net cholesterol absorption 
and flux from the intestine is altered in Cd36/ mice 
fed a cholic acid-supplemented LD. By way of compari-
son, we previously observed decreased intestinal choles-
terol absorption in chow-fed L-Fabp/ mice (12), yet we 
found no differences (from WT controls) in cholesterol 
absorption when those mice were fed the LD. These ob-
servations diminish the likelihood that genetically ma-
nipulated mice might be protected against gallstone 
formation simply by virtue of decreased intestinal cho-
lesterol absorption.
We considered an alternative hypothesis to account 
for the protection against gallstones in Cd36/ mice, 
namely, that compensatory adaptations in hepatic meta-
bolic pathways might mitigate the impact of LD-induced 
abnormalities. In considering this hypothesis, we were 
guided by prior findings demonstrating that hepatic CD36 
expression increases upon high-fat feeding (as in our 
LD model; Fig. 5C) (14) and also findings in a line of 
liver-specific Cd36 KO mice demonstrating protection 
against high-fat diet-induced hepatic steatosis, along with 
decreased hepatic fatty acid uptake (36). Other findings, 
however, have challenged the conclusions that hepatic 
fatty acid uptake is decreased in Cd36/ mice (31, 37). In 
particular, those studies pointed to a role for CD36 in 
regulating both de novo lipogenesis and also VLDL se-
cretion as key considerations (31, 37). The observation 
that hyperphagic ob/ob mice crossed into Cd36/ mice 
manifested increased hepatic steatosis because of de-
creased VLDL secretion (37) might have special rele-
vance to this discussion. This proposed function of CD36 
in regulating hepatic VLDL secretion reminded us of 
our previous findings that liver-specific Mttp deletion 
(Mttp-LKO mice) reduced LD-induced gallstone forma-
tion because we showed that crossing Mttp-LKO mice into 
L-Fabp/ mice conferred protection against LD-induced 
gallstones (38). Accordingly, those findings in ob/ob mice 
crossed into Cd36/ mice (37) reinforced the possibil-
ity that a hepatocyte-specific pathway of altered lipid 
metabolism (either altered de novo lipogenesis and/or 
decreased VLDL secretion) might attenuate gallstone sus-
ceptibility in Cd36-LKO mice. However, because this was 
not the case, we conclude that hepatocyte-specific func-
tions of CD36 cannot alone account for the gallstone pro-
tection phenotype observed in Cd36/ mice. We cannot 
definitively explain the observation that CD36 mRNA 
expression in whole liver extracts appeared to increase 
after LD feeding (Fig. 5C), although we recognize that 
other, nonhepatocyte populations (macrophages and 
Kupffer cells) express CD36 (17), and it is plausible that 
LD feeding induces adaptive increases in CD36 expres-
sion in these cell types. However, this possibility remains 
to be tested experimentally.
TABLE 2. Biliary lipid secretion in LD-fed mice of the indicated genotype
Genotype TC PL BA Flow rate
WT (12) 210.5 ± 6.9a 646.7 ± 14.9a 5103.8 ± 233.7a 91.6 ± 1.2
Cd36/ (7) 175.1 ± 8.6a 603.3 ± 24.1a 4827.9 ± 302.6a 89.3 ± 1.7
L-Fabp/ (9) 298.3 ± 11.9b 985.6 ± 39.9b 6907.5 ± 426.3b 115.9 ± 4.5
DKO (4) 221.8 ± 8.8ab 819.7 ± 31.9a 3900.1 ± 589.3a 83.2 ± 0.7
Mice from four experimental groups (n per group) were fed a LD for 2 weeks. Bile samples were collected after 
surgical laparotomy for 1 h. Biliary cholesterol (TC), phospholipids (PLs), and bile acids (BAs) were analyzed (Materials 
and Methods). Biliary lipid secretion is expressed as nmol/min/kg bw. Flow rate is expressed as µl/min/kg bw. The 
difference between values associated with different superscript letters for the parameters indicated in each vertical 
column is statistically significant (P < 0.05).
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secretin in Cd36/ mice (20). Nevertheless, it is impor-
tant to note that these contractility studies were conducted 
in vitro, and we did not independently validate changes in 
circulating CCK or secretin levels in Cd36/ mice fed a LD. 
In addition, although those prior studies demonstrated 
no change in gastric emptying in chow-fed Cd36/ mice 
(20), we did not independently examine intestinal transit 
or motility in LD-fed mice, as reported by others (34). 
Accordingly, conclusions regarding alterations in intes-
tinal motility and other details of gallbladder function 
that may be regulated by CD36 remain to be examined. 
However, we would predict that, because gallbladder CD36 
As a final consideration, we examined the possibility that 
altered smooth muscle function and, in particular, altered 
gallbladder motility might play a role in the protection ob-
served. Our observations point to yet another function for 
CD36, specifically in regulating gallbladder contractility. 
Several studies have demonstrated that reduced gallblad-
der and small intestinal motility promotes gallstone forma-
tion (19, 32, 34). Our current observations of increased 
gallbladder contractility along with the visual appear-
ance of smaller gallbladders in Cd36/ mice might appear 
somewhat unexpected, based on prior work demonstrating 
reduced enteroendocrine cell production of CCK and 
Fig. 3. Adaptive changes in hepatic and intestinal gene expression in LD-fed mice of the indicated genotypes. A, B: RNA was extracted 
from liver or scraped proximal intestinal mucosa, and mRNA abundance was determined by Real-time quantitative PCR. A: Hepatic mRNA 
expression. B: Proximal intestinal mRNA expression. C: NPC1L1 and SR-B1 protein expression in proximal intestinal mucosa. Thirty micro-
grams of protein was separated by SDS-PAGE gel, and the indicated proteins were detected by Western blot (upper). Band density was quan-
titated, and the data are presented as the mean ± SE (lower). D: Protein was extracted from terminal ileum and aliquots of total homogenate 
(Fgf15) or purified apical membranes (Asbt) separated on SDS-PAGE gel, and the indicated protein was detected by Western blot. The rela-
tive abundance of Fgf15 and Asbt were quantitated by using a Kodak image system, and the data are presented as the mean ± SE. *Statistically 
significant differences (P < 0.05).
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mRNA was unaltered in either Cd36-IKO or Cd36-LKO 
mice (Fig. 6C), it would be unlikely that a cross between the 
liver- and intestine-specific Cd36 KO lines would yield 
a gallstone protection phenotype. This prediction has 
yet to be tested, but at least raises, in principle, the possi-
bility (alluded to above) that alterations in yet other, cell-
specific CD36-dependent pathways might be relevant to 
gallstone pathogenesis.
Fig. 4. Intestine-specific Cd36 deletion does not protect against LD-
induced gallstone formation. Cd36-IKO mice and their littermate 
flox/flox controls were fed a LD for 4 weeks. A: Visible gallstones were 
observed in both genotypes (upper). Polarizing microscopy revealed 
aggregated ChMCs in both genotypes (lower; 200×). Gallstone inci-
dence (B), gallstone score (C) and gallbladder volume (D) was deter-
mined as described in Materials and Methods. E: Hepatic lipids were 
extracted and quantitated enzymatically (Materials and Methods). 
Hepatic lipid content is expressed as g/mg protein, except FFA, 
which is expressed as nmol/mg protein. The data in C–E represent 
the mean ± SE. n = 4–6 per group. BA, bile acid, CE, cholesteryl ester; 
FC, free cholesterol; PL, phospholipid; TC, total cholesterol.
Fig. 5. Hepatocyte-specific Cd36 deletion does not protect against 
LD-induced gallstone formation. Cd36-LKO mice were generated 
as described (Materials and Methods). A: DNA was extracted from 
hepatocytes (H) and the remnant, nonhepatocyte fraction of cells 
(O) after liver perfusion, and the DNA was analyzed by agarose gel. 
The hepatocyte fraction from Cd36- LKO mice shows Cre-mediated 
recombination. B: Hepatocytes were prepared from chow-fed Cd36-
LKO mice and flox/flox controls, and extracts were subjected to 
Western blotting for CD36. C: Whole liver extracts were prepared 
from Cd36-LKO mice and flox/flox controls fed LD for 4 weeks and 
Western-blotted for CD36. D: Visible gallstones were observed in 
both Cd36-LKO and littermate control gallbladders (representative 
gross appearances of gallbladder in upper). Polarizing microscopy 
revealed aggregated ChMCs in both genotypes (lower; 200×). Gall-
stone incidence (E), gallstone score (F), and gallbladder volume 
(G) were determined as described in Materials and Methods. H: 
Hepatic lipids were extracted and quantitated enzymatically (Mate-
rials and Methods). Hepatic lipid content is expressed as g/mg 
protein except FFA, which is expressed as nmol/mg protein. The 
data in C–E represent the mean ± SE. n = 4–6 per group. BA, bile 
acid, FC, free cholesterol; PL, phospholipid; TC, total cholesterol.
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